Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
NCT03690206 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG glepaglutide
Study Locations (20)
Other
- UZ Leuven — Leuven
- The Royal Alexandra Hospital — Edmonton
- Western University — London
- University Health Network - Toronto General Hospital — Toronto
- Aalborg University Hospital — Aalborg
- Rigshospitalet — Copenhagen
- Hôpital Beaujon — Clichy
- Centre Hospitalier Lyon-Sud — Pierre-Bénite
- Charité - Universitätsmedizin Berlin — Berlin
- Universitätsklinikum Bonn — Bonn
- Universitätsklinikum Frankfurt - Med. Klinik I — Frankfurt
- Asklepios Kliniken Hamburg GmbH — Hamburg
- Universitätsmedizin Rostock — Rostock
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Illinois
- University of Chicago Children's Hospital — Chicago
Minnesota
- Mayo Clinic College of Medicine — Rochester
Nebraska
- University of Nebraska Medical Center — Omaha
New York
- Mount Sinai Hospital — New York
Ohio
- Cleveland Clinic — Cleveland
Tennessee
- Vanderbilt University Medical Center, Nashville — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690206
The ClinicalTrials.gov registry entry for NCT03690206 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03690206 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, District of Columbia, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03690206 about?
NCT03690206 is a clinical study titled "Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)". The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
What is the current status of trial NCT03690206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2018-10-04. Estimated completion is 2022-07-26.
What conditions does trial NCT03690206 study?
This clinical trial studies the following conditions: Short Bowel Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03690206?
The interventions under investigation include: Placebo (DRUG), glepaglutide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03690206?
This trial is sponsored by Zealand Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03690206 being conducted?
This trial has 20 study locations across District of Columbia, Illinois, Minnesota, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.